Literature DB >> 33616779

Discounting in economic evaluation of healthcare interventions: what about the risk term?

Lars Hultkrantz1.   

Abstract

Results from economic evaluations of long-term outcomes are strongly dependent on the chosen discount rate. A recent review of national guidelines for evaluation of healthcare interventions finds that "the level of currently used discount rates seems relatively high in many countries". However, this conclusion comes from a comparison to rates derived or observed for investments in safe assets, while rate of return requirements are typically considerably higher when investment involves risk. This paper reviews recent literature on how to account for project-specific risk in determination of the social rate of discount and discusses implications for economic evaluation of healthcare interventions. It concludes that the available empirical evidence strongly suggests that the demand for and consumer value of health and healthcare is co-variant with income, which therefore implies that there is a non-diversifiable risk component of health-related investment.

Entities:  

Keywords:  Cost–benefit analysis; Project risk; Social discount rate

Mesh:

Year:  2021        PMID: 33616779      PMCID: PMC7954734          DOI: 10.1007/s10198-020-01257-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  4 in total

1.  On stationarity and cointegration of international health expenditure and GDP.

Authors:  U G Gerdtham; M Löthgren
Journal:  J Health Econ       Date:  2000-07       Impact factor: 3.883

2.  Social Security Income and Health Care Spending: Evidence from the Social Security Notch.

Authors:  Yuping Tsai
Journal:  Scand J Econ       Date:  2016-07-17

3.  Accounting for Timing when Assessing Health-Related Policies.

Authors:  Karl Claxton; Miqdad Asaria; Collins Chansa; Julian Jamison; James Lomas; Jessica Ochalek; Mike Paulden
Journal:  J Benefit Cost Anal       Date:  2019-01-26

Review 4.  Discounting in Economic Evaluations.

Authors:  Arthur E Attema; Werner B F Brouwer; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.